SCYNEXIS to Participate in Piper Sandler and Evercore ISI Conferences

Rhea-AI Summary

SCYNEXIS, a biotechnology firm focused on innovative medicines for drug-resistant infections, announced its participation in key healthcare conferences. The Piper Sandler 32nd Annual Virtual Healthcare Conference runs from November 23 to December 3, 2020, allowing registered attendees to access presentations from 8:00 a.m. to 5:00 p.m. ET. Additionally, SCYNEXIS will join a panel discussion at Evercore ISI’s HealthCONx Conference on December 2, 2020, from 11:20 a.m. to 12:05 p.m. ET, addressing critical fungal infection needs. Webcast recordings will be available on their website for 30 days.

JERSEY CITY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the Company’s participation in Piper Sandler’s 32^nd Annual Virtual Healthcare Conference. Presentations will be available for registered attendees via the Piper Sandler conference site from November 23 to December 3, 2020. The Company will also participate in a panel discussion at Evercore ISI’s 3^rd Annual HealthCONx Conference taking place on December 2, 2020.

Presentation details:

Piper Sandler 32nd Annual Virtual Healthcare Conference:
Presentation Date:	Monday, November 23 to Thursday, December 3, 2020
Presentation Time:	8:00 a.m. – 5:00 p.m. ET
Webcast:	Link
Evercore ISI 3rd Annual HealthCONx Conference:
Panel Discussion Topic:	No Fungus Among Us: Addressing an Important Need with Cidara, F2G, and SCYNEXIS
Presentation Date:	Wednesday, December 2, 2020
Presentation Time:	11:20 a.m. – 12:05 p.m. ET

A webcast of both presentation recordings will be available for 30 days and can be found on the Scynexis website at: https://www.scynexis.com/news-media/events.

About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to potentially help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Our lead candidate, ibrexafungerp (formerly known as SCY-078), is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class, in late stage development for multiple indications, ranging from vaginal yeast infections to life-threatening fungal infections in hospitalized patients. The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. For more information, visit www.scynexis.com.

CONTACT: 
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com

Media Relations
Gloria Gasaatura
LifeSci Communications
Tel: (646) 970-4688
ggasaatura@lifescicomms.com

 

FAQ

What are the dates for SCYNEXIS's participation in the Piper Sandler Virtual Healthcare Conference?

SCYNEXIS will participate in the Piper Sandler's conference from November 23 to December 3, 2020.

What time will SCYNEXIS present at the Piper Sandler conference?

SCYNEXIS's presentations will be available from 8:00 a.m. to 5:00 p.m. ET during the conference.

When will SCYNEXIS participate in the Evercore ISI HealthCONx Conference?

SCYNEXIS is scheduled to participate in the Evercore ISI HealthCONx Conference on December 2, 2020.

What is the topic for SCYNEXIS's panel discussion at the HealthCONx Conference?

The panel discussion topic is 'No Fungus Among Us: Addressing an Important Need with Cidara, F2G, and SCYNEXIS.'

How long will the webcasts of SCYNEXIS's presentations be available for viewing?

The webcasts will be available for 30 days on the SCYNEXIS website after the conferences.